Improving medication adherence. In real time.
Medication only works if it’s taken.
The Ategenos SmartPatch™ platform improves medication adherence by combining drug delivery with real-time non-adherence monitoring, helping patients and their caregivers avoid the adverse consequences of missed critical doses.
Foundational patent granted
Led by former Sandoz Inc. CEO
FDA 505(b)(2) pipeline initiated
Strategic partnerships in place
Medication non-adherence is one of healthcare’s most expensive and preventable problems.
Medication non-adherence drives over $500 billion in U.S. costs annually, $1 trillion globally, and 125,000 preventable deaths each year. We’re addressing multibillion-dollar markets by reformulating blockbuster, critical-dose medicines where adherence matters most.
So we’re pioneering a new PharmaTech solution.
Introducing SmartPatch™
Our proprietary platform combines advanced transdermal drug delivery with real-time adherence support to help patients avoid the adverse consequences of missed critical doses.
Reformulating oral solid-dose medications…
into transdermal SmartPatches…
that transmit real-time non-adherence data…
and alert caregivers of missed doses.
“We give caregivers peace of mind, knowing they can help their loved ones manage their critical dose medicines”
Don DeGolyer, CEO
The Ategenos SmartPatch™
The first connected therapeutic that passively delivers multi-day medication doses and detects non-adherence in real time. Our patented SmartPatch is backed by a growing IP portfolio covering key aspects of transdermal delivery, sensing, and connectivity. The Ategenos platform is defensible, differentiated, and built to scale.
This product is investigational, under development, and not yet cleared by the FDA for commercial distribution.
How It Works
Critical dose oral therapies are reformulated into easy-to-use, transdermal SmartPatches for sustained-release drug delivery.
SmartPatch microelectronics automatically track usage, and securely transmit reat-time updates via the cloud.
When a dose is missed, alerts prompt caregivers to intervene early, preserving quality of life and preventing hospitalizations or worse.
SmartPatch is an investigational platform not yet approved for commercial use.
See For Yourself
Our Pipeline Focus
Each SmartPatch candidate targets a branded therapy with an existing multibillion-dollar market and high clinical impact.
ATG-100: Cardiovascular Disease
ATG-200: Behavioral Health
ATG-300: GLP-1 Agonist
ATG-301: CNS
ATG-400: Oncology
Partner With Ategenos
Get Early Access to SmartPatch
Partnering pharma companies, payers, and health systems gain a first-mover advantage with the only scalable platform for connected drug delivery and non-adherence monitoring. You will be among the first to deploy this breakthrough technology across their networks.
For Pharmaceutical Companies
Target Multibillion-Dollar Markets: Reformulate branded drugs into SmartPatches unlocking new value in blockbuster categories
Lifecycle Management: Extend exclusivity and boost adherence
Real-World Evidence: Collect actionable data for payers and regulators
IP-Protected Platform: Partner with confidence on a platform protected by foundational patents and defensible claims
For Payers & Health Systems
Reduce avoidable costs from hospitalizations and complications
Improve medication adherence in community populations
Support independent living and better outcomes for at-risk patients
Join us to bring patients and caregivers the peace of mind they deserve.
Limited partnership opportunities available in 2025.
What Industry Leaders Are Saying
Our SmartPatch platform has been reviewed and validated by top executives in pharma, tech, and healthcare. Statements below reflect stakeholder enthusiasm for the concept and are not claims of performance or clinical outcomes. SmartPatch has not received FDA clearance.
About Ategenos
Improving medication adherence. In real time.
Ategenos is a Massachusetts-based PharmaTech company improving quality of life for patients and their families with its SmartPatch platform — an advanced transdermal system that combines sustained drug delivery with real-time monitoring and caregiver interventions. The technology reduces health risks, hospitalizations, and the $1T+ global costs caused by missed doses of critical medications. Ategenos's founding team combines global pharma leadership, MIT-driven innovation, and a proven history of building and scaling healthcare platforms from concept to commercialization.
Meet The Team
Don DeGolyer
-
A seasoned pharma exec with 35 years of experience
As President & CEO of Sandoz Inc., Don grew revenue by $2 billion in just four years, transforming the business into one of the world’s largest generics companies.
Previously, as COO of Endo, Don helped build a rapid-growth specialty pharmaceutical business, increasing market capitalization from $2 billion to $18 billion in only two years.
He also founded and served as Director of Vertice Pharmaceuticals, where he doubled revenue from $60 million to $120 million before a successful exit.
Additionally, Don has served as Senior Advisor at Koch Investment Group and Trialspark, and has held senior leadership positions at Pfizer, Johnson & Johnson, Novartis, and other leading healthcare companies.
William Kazman
-
A seasoned technology exec with 30 years of experience
Over the course of his career, Bill has founded three companies and served as a senior executive at six additional early-stage, high-growth technology and life science ventures.
An MIT-trained electrical engineer, Bill has a track record of pioneering advancements in telemedicine, connected care, Internet of Things (IoT), cloud networking, artificial intelligence, and embedded control systems. Over the years Bill has always worked to find transformative applications for cutting-edge technology.
George Lauro
-
A seasoned VC Exec with 30 years of experience
Throughout his career, George has managed four early-stage venture capital funds with a combined $2 billion under management, and has served as a Board Director for seven public companies and 26 private companies.
George has led multiple M&A and IPO exits, creating more than $2 billion in shareholder value. He has held senior leadership roles as Managing Director at Wasserstein Perella, Techfarm Ventures, and IBM’s Technology Commercialization division. George also co-acquired and operated Jazz Semiconductor alongside Apple co-founders Gil Amelio and Steve Wozniak.
Darren Miller
-
A seasoned technology exec with 28 years of experience
A biomedical engineer by training, Darren has extensive software architecture and development skills. He has experience working with everything from IoT devices to high-performance, Big Data enterprise platforms supporting payers, electronic health records (EHR), and other mission-critical systems.
Previously, Darren built and led a professional services team of more than 200 members at Ab Initio, a leading enterprise software solutions company.
News
JULY 22, 2025
Ategenos Announces Former Sandoz CEO Don DeGolyer as Co-Founder and CEO
AUGUST 5, 2025
Ategenos Secures Foundational Patent for SmartPatch Platform
UPCOMING…
Ategenos Debuts First-Ever SmartPatch Platform Addressing $1T Non-Adherence Crisis
For media inquiries, please contact media@ategenosrx.com.
Get In Touch
Work With Us
Whether you're a pharmaceutical innovator, payer, investor, or caregiver advocate, we want to hear from you. Fill out the form to contact our team.
Contact Info
Partnerships: partners@ategenosrx.com
Investment: invest@ategenosrx.com
Media: media@ategenosrx.com